OBJECTIVES: Trabectedin (ET-743, Yondelis) is a natural marine product, with antitumour activity, currently in phase II/III clinical trials. Previous studies have shown that cells hypersensitive to ultraviolet (UV)-rays because of nucleotide excision repair (NER) deficiency, were resistant to trabectedin. The purpose of this study was to investigate whether this resistance was associated with different drug-induced cell cycle perturbations. MATERIALS AND METHODS: An isogenic NER-proficient cellular system (CHO-AA8) and a NER-deficient one (CHO-UV-96), lacking functional ERCC-1, were studied. Flow cytometric assays showed progressive accumulation of cells in G2 + M phase in NER-proficient but not in NER-deficient cells. Applying a computer simulation method, we realized that the dynamics of the cell cycle perturbations in all phases were complex. RESULTS: Cells exposed to trabectedin during G1 and G2 + M first experienced a G1 block, while those exposed in S phase were delayed in S and G2 + M phases but eventually divided. In the presence of functional NER, exit from the G1 block was faster; then, cells progressed slowly through S phase and were subsequently blocked in G2 + M phase. This G2 + M processing of trabectedin-induced damage in NER-proficient cells was unable to restore cell cycling, suggesting a difficulty in repairing the damage. CONCLUSIONS: This might be due either to important damage left unrepaired by previous G1 repair, or that NER activity itself caused DNA damage, or both. We speculate that in UV-96 cells repair mechanisms other than NER are activated both in G1 and G2 + M phases.
OBJECTIVES: Trabectedin (ET-743, Yondelis) is a natural marine product, with antitumour activity, currently in phase II/III clinical trials. Previous studies have shown that cells hypersensitive to ultraviolet (UV)-rays because of nucleotide excision repair (NER) deficiency, were resistant to trabectedin. The purpose of this study was to investigate whether this resistance was associated with different drug-induced cell cycle perturbations. MATERIALS AND METHODS: An isogenic NER-proficient cellular system (CHO-AA8) and a NER-deficient one (CHO-UV-96), lacking functional ERCC-1, were studied. Flow cytometric assays showed progressive accumulation of cells in G2 + M phase in NER-proficient but not in NER-deficient cells. Applying a computer simulation method, we realized that the dynamics of the cell cycle perturbations in all phases were complex. RESULTS: Cells exposed to trabectedin during G1 and G2 + M first experienced a G1 block, while those exposed in S phase were delayed in S and G2 + M phases but eventually divided. In the presence of functional NER, exit from the G1 block was faster; then, cells progressed slowly through S phase and were subsequently blocked in G2 + M phase. This G2 + M processing of trabectedin-induced damage in NER-proficient cells was unable to restore cell cycling, suggesting a difficulty in repairing the damage. CONCLUSIONS: This might be due either to important damage left unrepaired by previous G1 repair, or that NER activity itself caused DNA damage, or both. We speculate that in UV-96 cells repair mechanisms other than NER are activated both in G1 and G2 + M phases.
Authors: M Minuzzo; S Marchini; M Broggini; G Faircloth; M D'Incalci; R Mantovani Journal: Proc Natl Acad Sci U S A Date: 2000-06-06 Impact factor: 11.205
Authors: R Garcia-Carbonero; J G Supko; J Manola; M V Seiden; D Harmon; D P Ryan; M T Quigley; P Merriam; J Canniff; G Goss; U Matulonis; R G Maki; T Lopez; T A Puchalski; M A Sancho; J Gomez; C Guzman; J Jimeno; G D Demetri Journal: J Clin Oncol Date: 2004-04-15 Impact factor: 44.544
Authors: M Ghielmini; E Colli; E Erba; D Bergamaschi; S Pampallona; J Jimeno; G Faircloth; C Sessa Journal: Ann Oncol Date: 1998-09 Impact factor: 32.976
Authors: Michela Romano; Matteo Giovanni Della Porta; Anna Gallì; Nicolò Panini; Simonetta Andrea Licandro; Ezia Bello; Ilaria Craparotta; Vittorio Rosti; Elisa Bonetti; Richard Tancredi; Marianna Rossi; Laura Mannarino; Sergio Marchini; Luca Porcu; Carlos M Galmarini; Alberto Zambelli; Marco Zecca; Franco Locatelli; Mario Cazzola; Andrea Biondi; Alessandro Rambaldi; Paola Allavena; Eugenio Erba; Maurizio D'Incalci Journal: Br J Cancer Date: 2017-01-10 Impact factor: 7.640
Authors: B Colmegna; S Uboldi; R Frapolli; S A Licandro; N Panini; C M Galmarini; Nadia Badri; V J Spanswick; J P Bingham; Konstantinos Kiakos; E Erba; J A Hartley; M D'Incalci Journal: Br J Cancer Date: 2015-12-03 Impact factor: 7.640